Democritus University of Thrace (DUTH)
Μελέτη της χημειοθεραπείας στη θεραπευτική αντιμετώπιση του κακοήθους μελανώματος: συσχέτιση με τη σταδιοποίηση της νόσου και αξιολόγηση νεότερων θεραπευτικών σχημάτων
Abstract
dc:descriptionThe malignant melanoma is a skin disorder quite easy in its diagnosis, particularly when it is presented on the skin, but difficult at the same time as the clinical points of the disease, often escape the Clinical Doctor’s attention. After the diagnosis of the malignancy, the target should be the complete control, aiming at the search of the focal point, of the guard of lymph gland and the correct classification of the disease. Many laboratory examinations follow in order to find possible metastases, as well as a proper information of the patient and his related environment regarding the disease, its stage and the confrontation of the melanoma with chemotherapy, as well as the likely side effects of this one in his organism. The most excellent collaboration of the Surgeon and the Chemotherapist Oncologist is also imposed for the correct further confrontation of the melanoma as well as the familiarization of all Doctors with the clinical picture of the melanocytic lessions, and the evasion of dulling concerning changes of nevoi. Social information and directives are required regarding the evasion of the sun-bathing, the use of sun protectors, as well as the correct use of sun glasses. At the General University Hospital of Alexandroupoli, in collaboration with the Oncological and Dermatological Clinic were diagnosed and faced 40 cases in the past few years according to the last chemotherapeutic data that are worldwide applied, contributing to the increase of survival and of the quality of life of these patients. The basic principles of the treatment that we applied for the confrontation of the advanced and metastatic melanoma, included the following therapeutic form: Dacarbazine, Temozolamide, high doses of interleukin-2, apart from patients with incurable cerebral metastases, Dacarbazine or temozolamide in combination and/or in combination with biological treatment (CDDP and vinblastine with or without IL-2 included, interferon alfa), Paclitaxel, Paclitaxel/CDDP, Paclitaxel/Carboplatin. Regarding the relapse of the disease and the therapeutic handlings that we applied depending on the stage of disease: the handlings were similar to those of primary therapy or adjuvant therapy that were mentioned before depending on the case. Also, many patients were not presented after the completion of the first treatments or they did not arrive for the established follow up after their completion. We should also report the cases of refusal to be submitted in chemotherapy -patients of final stage- preferring to end up in their residences near their family. From the study of our cases resulted the following conclusions: · The prevention and the surgical treatment in precocious stages is the best confrontation · The complementary treatment appears to benefit in the free of symptoms interval, but there are reserves for the profit in the total survival · The results of chemotherapy do not depend from the dosage of the therapeutic form · In the metastatic disease the combined chemotherapy has limited therapeutic results · Big intravenous doses of interleucine were accompanied with appreciable effectiveness, but were toxic with a lot of undesirable energies · The protocols of combination IL-2/IFN and the protocols of chemical immunotherapy increased the effectiveness but no profit was detected for the total survival · The non special immune irritation (IL-2, IFNs) has limited therapeutic correspondence The applied in our own cases therapeutic forms that had a direct relation to the stages of malignant melanoma, proved that cross-correlation of chemotherapy with the classification of disease is imposed for achievement of better possible therapeutic results, without the appearance of side effects from the toxicity of granted medicines. Furthermore, as they do not exist any proofs for the fact that chemotherapy improves the quality of life or that it has important effect on the survival, its use should be limited in cases of patients that present symptoms from the metastasis of malignant melanoma. Nevertheless, the improvement of symptoms and the increase of the total survival, criteria of success of chemotherapy, are judged exclusively with subjective criteria. From the above it is extracted that the DTIC factor on the one hand is the best chemotherapeutic factor in the confrontation of melanoma apart from the cases of metastatic malignant melanoma in the Central Nervous System and on the other hand constitutes the model with which the other therapeutic factors and the combinations of medicines should be appreciated from the Oncologist in the clinical practice.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karamarias, Georgios
- Καραμαρίας, Γεώργιος
Subjects
dc:subject × 14- Κακοήθες μελάνωμα
- Κλινική εικόνα κακοήθους μελανώματος
- Κλινικοιστολογική ταξινόμηση κακοήθους μελανώματος
- Χειρουργική θεραπεία κακοήθους μελανώματος
- Διαχείριση επιχώριων μεμφαδένων
- Συμπληρωματική θεραπεία
- Μεταστατικό μελάνωμα
- Ρόλος εμβολίων στο μελάνωμα
- Γονιδιακή θεραπεία
- Αντιαγγειογενετικοί παράγοντες
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21142